Achieve Life Sciences (ACHV) Short-Term Debt issuances (2022)
Achieve Life Sciences' (ACHV) quarterly Short-Term Debt issuances came in at -$169000.0 in Q4 2022, down 112.0% on a QoQ basis from $1.4 million in Q2 2022.
Powered by 
Analysis
Achieve Life Sciences (ACHV) Short-Term Debt issuances (2022) Analysis & Trends
Achieve Life Sciences (ACHV) has 1 years of Short-Term Debt issuances data on file, last reported at -$169000.0 in Q4 2022.
- Quarterly Short-Term Debt issuances changed N/A year-over-year to -$169000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $1.3 million (changed N/A YoY) and the FY2022 annual result came in at $1.3 million, changed N/A from the prior year.
- Short-Term Debt issuances fell to -$169000.0 in Q4 2022, from $1.4 million in the prior quarter.
- In the past five years, Short-Term Debt issuances ranged from a high of $1.4 million in Q2 2022 to a low of -$169000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Achieve Life Sciences | 369.90 Mn | 369.90 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | -169,000.00 |
| Jun 30, 2022 | 1.41 Mn |
| Mar 31, 2022 | 91,000.00 |